SQL remains a cornerstone skill for professionals across the data landscape, from data analysts and scientists to business intelligence specialists…
Read More
Anixa Biosciences Secures Key Patent for Breast Cancer Vaccine Technology in South Korea, Expanding Global Intellectual Property Portfolio
Anixa Biosciences has achieved a significant milestone in its quest to develop a preventive vaccine for breast cancer, securing a…
Read More
Angelini Pharma Acquires Catalyst Pharmaceuticals for $4.1 Billion to Bolster Rare Disease and Brain Health Portfolio
Angelini Pharma, a prominent player in the pharmaceutical sector, has announced a definitive agreement to acquire Catalyst Pharmaceuticals for an…
Read More
Gilead Sciences Reports Robust Q1 2026 Performance Driven by Strong HIV Portfolio and Promising PrEP Launches
Gilead Sciences has commenced 2026 with a demonstrably strong first quarter, reporting significant revenue growth primarily fueled by its leading…
Read More
Chiesi Acquires KalVista Pharmaceuticals for $1.9 Billion, Bolstering Rare Disease Portfolio with On-Demand HAE Treatment
In a landmark move that marks the largest acquisition in its 90-year history, Italian pharmaceutical giant Chiesi has agreed to…
Read More
BioMarin Pharmaceutical Finalizes $4.8 Billion Acquisition of Amicus Therapeutics, Bolstering Rare Disease Portfolio
BioMarin Pharmaceutical has officially concluded its substantial acquisition of Amicus Therapeutics, a move that promises to significantly expand BioMarin’s footprint…
Read More
Apotex Acquires Cumberland Pharmaceuticals’ Branded Drug Portfolio for $100 Million, Ushering in New Era for Both Companies
Canadian pharmaceutical giant Apotex has announced a significant strategic acquisition, agreeing to purchase Cumberland Pharmaceuticals’ entire portfolio of branded commercial…
Read More
Johnson & Johnson Forecasts Accelerated Growth in 2026 Driven by New Psoriasis Treatment, Icotyde, and Robust Pharma Portfolio
Johnson & Johnson (J&J) has reported a strong start to 2026, exceeding analyst expectations with robust first-quarter earnings and revising…
Read More
Everest Medicines Acquires Hasten Biopharmaceuticals for $250 Million to Bolster Asia Pacific Chronic Disease Portfolio and Commercial Reach
Everest Medicines, a leading biopharmaceutical company focused on developing and commercializing innovative medicines for chronic diseases, has announced a significant…
Read More
Biogen Acquires Apellis Pharmaceuticals for $5.6 Billion to Bolster Immunology and Rare Disease Portfolio
Biogen, a global biotechnology company renowned for its pioneering work in neuroscience, has announced a significant strategic acquisition of Apellis…
Read More
